Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis.
about
Nanoparticles for biomedical imaging: fundamentals of clinical translationNanodiscs as a Modular Platform for Multimodal MR-Optical ImagingContrast-enhanced micro-computed tomography using ExiTron nano6000 for assessment of liver injury.Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases.MRI in the early identification and classification of high-risk atherosclerotic carotid plaques.Insights into atherosclerosis using nanotechnologyMacromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probeA novel ligand-independent peptide inhibitor of TREM-1 suppresses tumor growth in human lung cancer xenografts and prolongs survival of mice with lipopolysaccharide-induced septic shock.Nature-inspired nanoformulations for contrast-enhanced in vivo MR imaging of macrophages.Nanoparticles as magnetic resonance imaging contrast agents for vascular and cardiac diseases.Diagnostic Magnetic Resonance Imaging of Atherosclerosis in Apolipoprotein E Knockout Mouse Model Using Macrophage-Targeted Gadolinium-Containing Synthetic Lipopeptide Nanoparticles.Recent Advances in Targeted, Self-Assembling Nanoparticles to Address Vascular Damage Due to Atherosclerosis.Molecular imaging of retinal disease.Nanocrystal Core Lipoprotein Biomimetics for Imaging of Lipoproteins and Associated Diseases.Targeting and therapeutic peptides in nanomedicine for atherosclerosis.High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis.Modified natural nanoparticles as contrast agents for medical imaging.Cardiovascular MRI in small animals.Bioabsorbable stent quo vadis: a case for nano-theranostics.Nanobiotechnology applications of reconstituted high density lipoprotein.Standardization of models and methods used to assess nanoparticles in cardiovascular applications.Emerging engineered magnetic nanoparticulate probes for targeted MRI of atherosclerotic plaque macrophages.Nanomedicine in cardiovascular therapy: recent advancements.Molecular MRI of atherosclerosis.Visualizing the atherosclerotic plaque: a chemical perspective.Nanotechnology for the detection and therapy of stroke.Molecular magnetic resonance imaging of atherosclerotic vessel wall disease.Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging.Lipoproteins and lipoprotein mimetics for imaging and drug delivery.Detection and treatment of atherosclerosis using nanoparticles.HDL as a contrast agent for medical imaging.Molecular MRI of Inflammation in Atherosclerosis.Collagen-specific peptide conjugated HDL nanoparticles as MRI contrast agent to evaluate compositional changes in atherosclerotic plaque regression.Detection of macrophages via paramagnetic vesicles incorporating oxidatively tailored cholesterol ester: an approach for atherosclerosis imaging.The time window of MRI of murine atherosclerotic plaques after administration of CB2 receptor targeted micelles: inter-scan variability and relation between plaque signal intensity increase and gadolinium content of inversion recovery prepared versu
P2860
Q28385644-FEDCEB62-1816-44E6-B15B-984DC9A79389Q28397423-BEABB863-2D5B-45E8-B4CA-26A47EDC173AQ30406780-FD3D8E5B-58D2-479B-832C-28303A61045CQ30475719-B7CC1CFD-56FB-494B-831A-46EE1A4ADC71Q30478391-4ECAE44E-0808-4DA9-B90B-7EA68D21CA62Q33824820-3385A76F-3762-411F-A9CB-7F241C2D37D0Q33847006-A63AE565-3496-442E-B3D8-8F00688C05DFQ33868758-530EC02F-B1D4-47C8-B204-BA0119123A54Q33869944-B5338598-A00C-4CA3-B8F8-36E2249A2B9EQ34339353-09AC9040-2B2D-4851-9CDB-2B2D83E07B43Q35667247-BD30227F-18DD-43CA-87E3-462C1B28DF96Q35841557-882B7B0C-251E-43B9-B395-2A82E6578DE0Q36598388-9D2B82C7-FD8F-4CC2-8E71-47E5167FB454Q36696874-CAF2A0CF-7FF9-48F8-A1C0-91FCFC2E5667Q36841990-6504C9C0-B619-4125-B696-45F12C3D64E0Q36913594-6EFD8C8F-7D35-4232-8791-319514CE7750Q37611333-8F0E3C30-6B05-46F4-85D3-C055103A42CDQ37629944-0A071B38-3BD0-4ECE-B2C4-CD99CE6AD0F9Q37656278-2598FBA9-3634-4358-ADFE-209F029300A1Q37663672-9B7EE4FA-FD87-4270-A3D9-80CCEAE8F461Q37814488-CB960DB0-BCD9-4893-A027-E480B3CF3552Q37841416-2FA90811-AA11-433E-9D1D-084F7E558F52Q38013147-41575674-3E9B-46EA-9B78-9377E50775D0Q38034812-AFC8DB30-BB1F-464B-83DE-818159F65E9EQ38162728-8B718473-B1B6-45A9-ADCF-2902B5A23559Q38187881-FB79EDD4-7BDA-438E-9180-E899E8B05DBCQ38201415-699141BA-960A-4322-9633-89BEDA67D391Q38542308-E3F54EBF-38E9-4AA1-9CFF-4C11E535DAC1Q38548184-07772638-2168-4A4E-9E84-9D3E74691971Q38822339-B165AE57-6832-4B56-94AA-45BE764D6E40Q38848673-E5EB39C3-0916-42FF-89DB-9F9C46196889Q39813598-E50B0F0C-C10E-4B6A-9AA8-03B580B5082EQ40509301-F942AB0A-E2BA-43AD-A5A6-6E624F34FD8EQ40676096-6944F42D-4769-40B3-AFA9-77898EB0FA75Q42736765-30E9AD00-D89E-4A84-8FEC-B2A1D2F58075Q53270045-584DBB8B-8B3A-4E24-B097-38D2F1C43ACC
P2860
Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Incorporation of an apoE-deriv ...... acrophages in atherosclerosis.
@ast
Incorporation of an apoE-deriv ...... acrophages in atherosclerosis.
@en
type
label
Incorporation of an apoE-deriv ...... acrophages in atherosclerosis.
@ast
Incorporation of an apoE-deriv ...... acrophages in atherosclerosis.
@en
prefLabel
Incorporation of an apoE-deriv ...... acrophages in atherosclerosis.
@ast
Incorporation of an apoE-deriv ...... acrophages in atherosclerosis.
@en
P2093
P2860
P50
P356
P1476
Incorporation of an apoE-deriv ...... acrophages in atherosclerosis.
@en
P2093
Alessandra Barazza
Eik Leupold
Esad Vucic
Margitta Dathe
Willem J M Mulder
Zahi A Fayad
P2860
P304
P356
10.1002/CMMI.257
P577
2008-11-01T00:00:00Z